• Active, not recruiting

NCT01421524: Phase 1: Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness

Updated: Sep 27

NCT01421524: Phase 1: Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma

cc122

The main purpose of this first in human study with CC-122 is to assess the safety and action of a new class of experimental drug (Pleiotropic Pathway Modulator) in patients with advanced tumors unresponsive to standard therapies and to determine the appropriate dosing level and regimen for later-stage clinical trials.


Sponsor

Celgene

 

ClinicalTrials.gov Identifier: NCT01421524

Official Title: A Phase 1a/1b, Multi-center, Open-label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the Pleiotropic Pathway Modifier CC-122 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma.

First Posted : August 23, 2011

Click here to see details on ClinicalTrials.gov

 

Drug: CC-122

Avadomide (Code C160786)

Avadomide (Code C160786)


Avadomide (Code C160786)

2,6-Piperidinedione, 3-(5-amino-2-methyl-4-oxo-3(4H)-quinazolinyl)-

Avadomide

AVADOMIDE

CC 122

CC-122

CC122

 

Blood;2020

Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier

https://pubmed.ncbi.nlm.nih.gov/31977002/







Posts Archive